Despite these data, the experts could not meet consensus on the use of triplet or quadruplet regimens according to the presence of hepatic/brain metastasis, LIPI and LDH score, advanced age, performance status = 2, non-adenocarcinoma histology, negative PD-L1, and high disease burden, suggesting that subgroup analyses and these features are not independent factors guiding treatment choice. The gene discussed is CD274; the disease is adenocarcinoma.